Trials / Completed
CompletedNCT03982355
Development and Validation of a Tumour Oxygenation Monitoring Probe
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.
Detailed description
Tumour hypoxia is feature common to most solid tumours, with significant implications in tumour aggressiveness, metastatic potential and response to therapy. Tumour oxygenation monitoring is likely, therefore, to provide a valuable adjunct in risk stratification and treatment response monitoring. Diffuse reflectance spectroscopy (DRS) utilises the differing absorption of oxygenated as compared to deoxygenated haemoglobin to provide an accurate measure of tissue oxygenation. This project aims to develop and validate a tissue oxygenation probe for cancer monitoring. Using the clinical paradigms of rectal and breast cancer, anonymised MRIs of cancer sufferers will guide simulations of tissue optical properties to develop a DRS probe. The 3D reconstructed sans will then be used to 3D print tissue phantom models on which the DRS probe will be validated against reference bench top analysers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | DRS probe | The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe |
Timeline
- Start date
- 2019-08-09
- Primary completion
- 2020-06-30
- Completion
- 2020-06-30
- First posted
- 2019-06-11
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03982355. Inclusion in this directory is not an endorsement.